Pacira Biosciences Inc
Change company Symbol lookup
Select an option...
PCRX Pacira Biosciences Inc
GOOG Alphabet Inc
IGXT Intelgenx Technologies Corp
DGX Quest Diagnostics Inc
MDLZ Mondelez International Inc
FE FirstEnergy Corp
CADE Cadence Bancorp
SCHD Schwab U.S. Dividend Equity ETF™
ARKK ARK Innovation ETF
URANF International Prospect Ventures Ltd
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Closing Price
$64.45
Day's Change
-0.65 (-1.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
65.76
Day's Low
63.52
Volume
(Below Average)
Volume:
371,997

10-day average volume:
433,619
371,997

PCRX's position in the Pharmaceuticals industry

Industry PeersPCRXSUPNCOLLANIPBDSI

Summary

Company ProfilePacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of...
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR...
Go to SUPN summary
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology...
Go to COLL summary
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The...
Go to ANIP summary
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of...
Go to BDSI summary
52-Week Change

VS. INDUSTRY
69.47%
72.74%
13.84%
-18.74%
-17.10%
Market Cap

VS. INDUSTRY
$2.9B
$1.7B
$818.8M
$422.6M
$344.9M
Beta

VS. INDUSTRY
1.1
1.3
1.0
1.3
0.7
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
19.84x
13.28x
30.58x
--
14.11x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$429.6M
$520.4M
$310.0M
$208.5M
$156.5M
Profit Margin

VS. INDUSTRY
33.87%
24.39%
8.63%
-10.82%
16.43%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
136.59%
53.00%
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
2.05%
32.50%
4.49%
0.93%
40.47%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.